Omni Partners US’s Humacyte HUMA Stock Holding History

Omni Partners US’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-191,925	Closed	-$1.96M	–	249
2021 Q2	$1.96M	Buy	+191,925	New	+$1.98M	0.09%	118

Other funds holding HUMA

YCMGA

York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

DCP

Diameter Capital Partners New York $1.07B AUM 152.29% 1-Year Est. Return

MIM

Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Omni Partners US's HUMA Position: Q3 2021 in Review

Omni Partners US sold out of Humacyte (HUMA) in Q3 2021, closing a stake of 191,925 shares — an estimated $1.96M sold.

Omni Partners US first reported a position in HUMA in Q2 2021 and held it in 1 quarter. The position peaked at $1.96M in Q2 2021. 32 funds tracked by Wall St. Rank hold HUMA as of Q3 2021.

Omni Partners US reported no remaining Humacyte position as of Q3 2021 after selling out during the quarter.
Omni Partners US sold 191,925 Humacyte shares in Q3 2021, an estimated $1.96M.
Omni Partners US first reported a position in Humacyte in Q2 2021 and held it in 1 quarter.
Omni Partners US's Humacyte position peaked at $1.96M in Q2 2021.
32 funds tracked by Wall St. Rank held Humacyte as of Q3 2021.

Based on Omni Partners US's 13F filing for Q3 2021, filed 15 Nov 2021.